文献速递糖尿病

GAD-铝免疫治疗在新诊断1型糖尿病中的疗效与HLA-DR3-DQ2相关

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.
PubMed 文献 · Diabetologia · 2020-08-05

本研究利用三项安慰剂对照随机临床试验的个体患者数据,评估GAD-铝免疫治疗对新诊断1型糖尿病患者C肽保留的HLA依赖性疗效。混合重复测量模型显示,在携带HLA-DR3-DQ2(伴或不伴HLA-DR4-DQ8)的个体中,较高剂量(三次或四次注射)GAD-铝治疗较安慰剂显著且剂量依赖性地改善C肽保留。

要点

  • 在HLA-DR3-DQ2阳性(不含DR4-DQ8)个体中,较高剂量GAD-铝治疗较安慰剂的疗效比为1.596(95%CI 1.132, 2.249;校正P=0.0035)。
  • 在全部HLA-DR3-DQ2阳性(含DR4-DQ8阳性)个体中,较高剂量GAD-铝治疗较安慰剂的疗效比为1.441(95%CI 1.188, 1.749;校正P=0.0007)。
  • GAD65特异性免疫治疗对新诊断1型糖尿病且携带DR3-DQ2单倍型的个体C肽保留有显著影响。

核心结论

  • GAD65特异性免疫治疗对新诊断1型糖尿病且携带DR3-DQ2单倍型的个体C肽保留有显著影响。

研究设计与样本

  • 研究使用三项安慰剂对照随机临床试验的个体患者数据,采用混合重复测量模型评估GAD-铝治疗对新诊断1型糖尿病患者C肽保留的HLA依赖性疗效。

主要发现

  • 在携带HLA-DR3-DQ2但不携带HLA-DR4-DQ8的个体中,较高剂量(三次或四次注射)GAD-铝治疗较安慰剂的疗效比为1.596(95%CI 1.132, 2.249;校正P=0.0035)。
  • 在全部携带HLA-DR3-DQ2的个体(包括同时携带HLA-DR4-DQ8者)中,较高剂量(三次或四次注射)GAD-铝治疗较安慰剂的疗效比为1.441(95%CI 1.188, 1.749;校正P=0.0007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to determine if retention of C-peptide following immunotherapy using recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum) is influenced by HLA risk haplotypes DR3-DQ2 and DR4-DQ8. METHODS: HLA-dependent treatment effect of GAD-alum therapy on C-peptide retention in individuals with recent-onset type 1 diabetes was evaluated using individual-level patient data from three placebo-controlled, randomised clinical trials using a mixed repeated measures model. RESULTS: A significant and dose-dependent effect was observed in individuals positive for the genotypes that include HLA-DR3-DQ2 but not HLA-DR4-DQ8 and in the broader subgroup of individuals positive for all genotypes that include HLA-DR3-DQ2 (i.e. including those also positive for HLA-DR4-DQ8). Higher doses (three or four injections) showed a treatment effect ratio of 1.596 (95% CI 1.132, 2.249; adjusted p = 0.0035) and 1.441 (95% CI 1.188, 1.749; adjusted p = 0.0007) vs placebo for the two respective HLA subgroups. CONCLUSIONS/INTERPRETATION: GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hannelius U, Beam CA, Ludvigsson J, et al. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. Diabetologia. 2020. PMID: 32754804. doi:10.1007/s00125-020-05227-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。